Santen Pharmaceutical announced that it had transferred Advanced Vision Science (AVS), its wholly owned subsidiary, to SpyGlass Pharma. The transfer is intended to optimize the company's business portfolio, and AVS is engaged in the development, manufacture and sale of ophthalmic medical devices, mainly IOLs.
Santen Pharmaceutical announced that it had transferred all issued shares of Advanced Vision Science (AVS), its wholly owned subsidiary in California, US, to SpyGlass Pharma, which develops solutions in the ophthalmology field. The transfer was carried out as part of the optimization of its business portfolio, and AVS has been engaged in the development, manufacture and sale of medical devices for ophthalmology. Santen Pharmaceutical stated that it will continue to provide innovative products and services in the ophthalmology field.
Through the acquisition of AVS, SpyGlass is expected to strengthen its manufacturing capacity and continue product development in the ophthalmology field. AVS will continue to manufacture and supply IOL products primarily for Santen Pharmaceutical, while Santen Pharmaceutical plans to continue its IOL business in Japan.